Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Phase 2

Completed

Conditions: Stage IV Prostate Cancer
Hormone-resistant Prostate Cancer
Adenocarcinoma of the Prostate
Recurrent Prostate Cancer

Interventions: Drug: Hsp90 inhibitor STA-9090
Other: laboratory biomarker analysis
Genetic: polymerase chain reaction
Other: enzyme-linked immunosorbent assay
Genetic: RNA analysis
Other: spectrophotometry
Genetic: reverse transcriptase-polymerase chain reaction
Genetic: gene expression analysis

Registration Number: NCT01270880

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Brief Summary: Hsp90 inhibitor STA-9090 may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. This phase II trial is studying how well Hsp90 inhibitor STA-9090 works in treating patients with metastatic hormone-resistant prostate cancer previously treated with docetaxel-based chemotherapy

Detailed Description: PRIMARY OBJECTIVES:

I. To evaluate progression-free survival (PFS) achieved with STA-9090 (Hsp90 inhibitor STA-9090) in men with castration-resistant prostate cancer (CRPC) who have received prior docetaxel based therapy.

SECONDARY OBJECTIVES:

I. To assess the percentage change in prostate-specific antigen (PSA) from baseline to 12 weeks.

II. To assess overall safety and tolerability of STA-9090. III. To evaluate overall survival (OS) outcome in metastatic CRPC who have received prior docetaxel therapy.

IV. To investigate the association of progression-free survival (PFS) and PSA response rate with primary and secondary target markers.

TERTIARY OBJECTIVES:

I. To evaluate potential markers for predicting drug response or efficacy, blood samples will be used to collect the serum and extract messenger ribonucleic acid (mRNA) from mononuclear cells and analyzed by quantitative real-time polymerase chain reaction (PCR) and/or enzyme-linked immunosorbent assay (ELISA).

OUTLINE:

Patients receive Hsp90 inhibitor STA-9090 intravenously (IV) over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 4 weeks.

Recruitment & Eligibility

Status: COMPLETED

Sex: Male

Target Recruitment: 18

Inclusion Criteria

Pathologically confirmed diagnosis of prostate adenocarcinoma with metastasis and objective progression or rising PSA despite androgen deprivation therapy and antiandrogen withdrawal when applicable
Progression after docetaxel based chemotherapy is needed as follows:
a) If measurable disease present, then either rising PSA, increase in size of the lesion/s or both should be present
b) Patients with rising PSA only as progression must demonstrate a rising trend with 2 successive elevations at minimum intervals of 1 week; a minimum PSA of 5 ng/ml, or new areas of bony metastases on bone scan are required for patients with no measurable disease; no minimum PSA requirement for patients with measurable disease
Patients should have received at least one prior docetaxel based regimen for metastatic disease; no maximum prior therapy
Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2
Life expectancy of at least 3 months
Prior radiation therapy or chemotherapy completed at least 28 days prior to enrollment
All patients must be documented to be castrate with a testosterone level =< 0.5 ng/ml; luteinizing-hormone-releasing hormone (LHRH) agonist therapy must be continued, if required to maintain castrate levels of testosterone; patients must be off antiandrogens for a minimum of 4 weeks for flutamide and 6 weeks for bicalutamide or nilutamide
Absolute neutrophil count >= 1,500 cells/uL
Platelets >= 100,000/uL
Hemoglobin >= 9.0 g/dL
Serum creatinine =< 1.5 x upper limit of normal (ULN); Note: if serum creatinine is > 1.5 x ULN, subject is eligible if the calculated creatinine clearance (CLcr) is >= 50 mL/min
Total bilirubin =< 1.5 x ULN
For patients without documented bone metastases or for patients with liver metastases: transaminases (aspartate aminotransferase [AST]/serum glutamic oxaloacetic transaminase [SGOT] and/or alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase [SGPT]) may be up to 2.5 x institutional ULN if alkaline phosphatase is =< ULN, or alkaline phosphatase may be up to 4 x ULN if transaminases are =< ULN
For patients with documented bone metastases, the transaminases (AST/SGOT and/or ALT/SGPT) should be less than 2.5 x institutional ULN, without regard to the alkaline phosphatase level
Sexually active males must use measures to prevent pregnancy in their partners while on STA-9090
Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
Ability to understand and willingness to sign a written informed consent document

Exclusion Criteria

Major surgery within 4 weeks prior to first dose of STA-9090
Poor venous access for study drug administration or would require a peripheral or central indwelling catheter for study drug administration; study drug administration via indwelling catheters is prohibited at this time
Use of any chemotherapy or other standard systemic treatments for prostate cancer, including investigational agents within 2 weeks or 6 half- lives of the agent, whichever is shorter, prior to receiving STA-9090; there must be at least 2 weeks between the end of palliative radiation and the start of study drug and all radiation therapy (XRT)-associated toxicities resolved to Grade 1 or 0
History of severe allergic or hypersensitivity reactions to excipients (e.g., Polyethylene glycol [PEG] 300 and Polysorbate 80 [i.e. docetaxel])
Baseline QTc > 450 msec or previous history of QT prolongation while taking other medications
Ventricular ejection fraction (Ef) =< 55% at baseline
Any history of current coronary artery disease, myocardial infarction, angina pectoris, angioplasty or coronary bypass surgery
History of current uncontrolled dysrhythmias, or requirement for antiarrhythmic medications, or Grade 2 or greater left bundle branch block
New York Heart Association class II/III/IV congestive heart failure with a history of dyspnea, orthopnea, or edema that requires current treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers or diuretics
Current or prior radiation therapy to the left hemithorax
Treatment with chronic immunosuppressants (e.g. cyclosporine following transplantation)
Uncontrolled intercurrent illness including, but not limited to, human immunodeficiency virus (HIV)-positive subjects receiving combination antiretroviral therapy, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, ventricular arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Other medications, or severe acute/chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the subject inappropriate for entry into this study

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment (enzyme inhibitor therapy)	polymerase chain reaction	Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Treatment (enzyme inhibitor therapy)	reverse transcriptase-polymerase chain reaction	Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Treatment (enzyme inhibitor therapy)	laboratory biomarker analysis	Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Treatment (enzyme inhibitor therapy)	spectrophotometry	Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Treatment (enzyme inhibitor therapy)	enzyme-linked immunosorbent assay	Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Treatment (enzyme inhibitor therapy)	RNA analysis	Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Treatment (enzyme inhibitor therapy)	gene expression analysis	Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Treatment (enzyme inhibitor therapy)	Hsp90 inhibitor STA-9090	Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measures

Name	Time	Method
PFS Proportion Achieved With STA-9090 in Men With CRPC Who Have Received Prior Docetaxel Based Therapy	At 6 months	Our primary objective was to determine the 6-month PFS rate by using a binary (yes/no) endpoint of 6 months of PFS. Treatment success was defined as achievement of at least 6 months of PFS. Patients who did not complete 6 months of ganetespib therapy for any reason (including death from any cause) were considered treatment failures and were recorded as not achieving the primary endpoint.

Secondary Outcome Measures

Name	Time	Method
Percentage Change in PSA	From baseline to 12 weeks	Percentage change in PSA from baseline.
Overall Safety and Tolerability of STA-9090	Day 1, 8, and 15 of each course and at end of treatment	Overall safety and tolerability of STA-9090 by total number of grade 3 adverse events
OS in Metastatic CRPC Who Have Received Prior Docetaxel Therapy	From first dose to death or the date last known alive	Overall Survival (OS) in metastatic Castrate Resistant Prostate Cancer (CRPC) who have received prior docetaxel therapy using Kaplan-Meier method
Association of PFS With PSA	At 6 months	Association of PFS with PSA using Cox PH regression model
Potential Markers for Predicting Drug Response or Efficacy	At baseline, day 1 of course 3, and end of treatment	Potential markers for predicting drug response or efficacy : This is not a measurable outcome, but a possible entity for further study.

Trial Locations

Locations (4): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital
🇺🇸
Baltimore, Maryland, United States
University of Medicine nd Denistry of New Jersey
🇺🇸
Piscataway, New Jersey, United States
Karmanos Cancer Institute
🇺🇸
Detroit, Michigan, United States
University of Wisconsin Cancer Center Riverview
🇺🇸
Wisconsin Rapids, Wisconsin, United States